Drugs / SM-1
SM-1
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07635173 | Sep 2022 → Apr 2024 | glioblastoma | Shenzhen Zhenxing Medical Technology Co., Ltd | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SM-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07635173 ↗ |
| Known as | Obitazidine Fumarate | “Obitazidine Fumarate Enteric-coated Pellet Capsules (SM-1) in Combination With Temozolomide in Subjects With Refractory or Recurrent Gliomas: Phase I Trial” NCT07635173 ↗ |
| Known as | Obitrexate Fumarate | “SM-1 (Obitrexate Fumarate Enteric-coated Pellet Capsules)” NCT07635173 ↗ |
| Route | Oral | “SM-1 is given orally once daily in the morning on an empty stomach” NCT07635173 ↗ |